In a clinical trial, the sponsor carries ultimate responsibility for the investigational product, and the clinical investigator at each study site is directly responsible for how that product is handled and used with participants. That split is the answer to the question of who is responsible for investigational products in clinical trials: the sponsor answers at the highest level for the product itself, and the investigator answers for what happens with it on the ground. Federal regulations put both roles in writing, and neither can be signed away by hiring a contract research organization or delegating tasks to study staff.
What the Sponsor Must Do
The sponsor is the entity that initiates and takes responsibility for a clinical investigation. That can be a pharmaceutical company, a biotech, a government agency, or an academic institution. Under 21 CFR 312.50, a drug sponsor must select qualified investigators, give them the information they need to run the study properly, monitor the investigation, keep the IND current with the FDA, and make sure everyone involved hears about new safety risks promptly.1GovInfo. 21 CFR 312.50 – General Responsibilities of Sponsors For investigational devices, 21 CFR Part 812 imposes nearly identical duties.2eCFR. 21 CFR 812.40 – General Responsibilities of Sponsors
The practical effect is that the sponsor cannot hand the product to investigators and walk away. Active oversight is the whole point of the role.
Informing Investigators
Before the study begins, the sponsor must provide each investigator with an investigator brochure covering everything known about the drug, including preclinical data, prior clinical experience, and known risks. As the investigation continues, the sponsor must relay new safety findings through updated brochures, published reports, or direct letters.3eCFR. 21 CFR 312.55 – Informing Investigators If the sponsor learns about a dangerous side effect and an investigator never hears about it, that failure sits on the sponsor.
Monitoring and Stopping Problems
The sponsor must monitor every site. If a sponsor discovers that an investigator is not following the protocol or the regulations, the sponsor must either bring that investigator back into compliance or cut them off, stop shipping the drug to that site, and notify the FDA. When a sponsor determines the drug poses an unreasonable risk to participants, the sponsor must shut down the affected studies within five working days, notify the FDA and every IRB, arrange for return or destruction of remaining drug supplies, and file a full report.4eCFR. 21 CFR 312.56 – Review of Ongoing Investigations
Safety Reporting
Safety reporting is the sponsor’s most time-sensitive duty. For a suspected adverse reaction that is both serious and unexpected, the sponsor must notify the FDA and all participating investigators within 15 calendar days of determining that the event qualifies for reporting. If the reaction is fatal or life-threatening, the initial report must reach the FDA within seven calendar days. Reporting is not limited to events at the sponsor’s own trial sites. Findings from epidemiological studies, pooled analyses, animal testing, or in vitro data that suggest a significant risk to humans exposed to the drug also trigger reporting requirements.5eCFR. 21 CFR 312.32 – IND Safety Reporting A sponsor that tracks only its own trial data and ignores outside signals can end up in serious regulatory trouble.
Supplying and Disposing of the Product
The sponsor supplies the investigational product to each site and should not ship it until all required regulatory and IRB approvals are in place. The sponsor also provides written procedures covering how sites should receive, store, dispense, and return the product.6ICH. ICH E6(R2) Guideline for Good Clinical Practice On the back end, the sponsor must ensure that unused supplies are returned from each investigator whose participation ends. An alternative method of disposal is allowed only if it does not expose anyone to risk from the drug, and all disposition records must be maintained in writing.7eCFR. 21 CFR 312.59 – Disposition of Unused Supply of Investigational Drug Tracking every shipment, receipt, return, and destruction, and being able to retrieve product in the event of a recall, is the sponsor’s problem too.
What the Investigator Must Do at the Site
The clinical investigator is directly responsible for how the trial runs at the study location. Federal regulations require the investigator to conduct the study according to the signed investigator statement and the investigational plan, to protect the safety and welfare of participants, and to control the investigational drug.8eCFR. 21 CFR 312.60 – General Responsibilities of Investigators
Informed Consent
Before enrolling anyone, the investigator must obtain informed consent that covers the purpose of the research, expected duration of participation, foreseeable risks, and whether compensation or medical treatment is available if injury occurs.9eCFR. 21 CFR 50.25 – Elements of Informed Consent The consent document must be signed and dated, and the case history for each participant must show that consent was obtained before any study procedures began.10eCFR. 21 CFR 312.62 – Investigator Recordkeeping
Drug Accountability and Records
The investigator must keep records of what happens to every unit of the drug: dates received, quantities, and which participants received them. When the study ends or the investigator’s involvement is discontinued, unused supplies must be returned to the sponsor or disposed of according to the sponsor’s instructions. Case histories recording all observations and data for each participant must be retained for two years after a marketing application is approved, or two years after the investigation is discontinued, whichever applies.10eCFR. 21 CFR 312.62 – Investigator Recordkeeping
Delegation Without Handing Off Accountability
An investigator can delegate specific study tasks to sub-investigators, research coordinators, and other staff, but delegation does not transfer accountability. The investigator remains fully responsible for everything that happens at the site. Good Clinical Practice guidelines expect a delegation log listing every person performing significant trial-related duties, describing the tasks delegated, confirming their qualifications, and recording their dates of involvement. FDA inspectors look at these logs closely, because gaps often signal deeper problems with site oversight.
When One Person Wears Both Hats
In academic and government-funded research, a single individual frequently initiates a study, secures the funding, and personally conducts the investigation. The regulations call this person a sponsor-investigator, and the responsibilities that apply to both sponsors and investigators fall on that one individual.11eCFR. 21 CFR 312.3 – Definitions and Interpretations That means IND filings, safety reporting, investigator brochure updates, product accountability, participant safety, and recordkeeping all sit with the same person, and the FDA holds sponsor-investigators to the same standards as a large corporate sponsor. The administrative workload is often underestimated at the outset.
Delegating to a Contract Research Organization
Sponsors can transfer some or all of their regulatory obligations to a contract research organization. The transfer must be in writing, and if only certain duties are delegated, the written agreement must specify exactly which ones. Any obligation not described in that agreement stays with the sponsor.12eCFR. 21 CFR 312.52 – Transfer of Obligations to a Contract Research Organization
A CRO that takes on a sponsor obligation becomes subject to the same regulatory enforcement as the sponsor for that obligation. Every reference to “sponsor” in the regulations applies to the CRO for any duty it has assumed.12eCFR. 21 CFR 312.52 – Transfer of Obligations to a Contract Research Organization Even so, the sponsor still needs to oversee the CRO’s work. Regulators will not accept “we hired a CRO to handle that” as a defense if the CRO fails to perform a critical function like safety reporting. The sponsor chose the CRO, defined the scope, and is expected to verify performance.
Where IRBs and the FDA Fit In
Neither Institutional Review Boards nor the FDA hold operational responsibility for the investigational product itself. Their role is oversight, not management. An IRB must review and approve the protocol and consent materials before enrollment, conduct continuing review, and approve any changes to an ongoing study unless a change is needed to eliminate an immediate safety hazard. An IRB can suspend or terminate a study if it finds that participant safety is being compromised.13eCFR. 21 CFR 56.108 – IRB Functions and Operations
The FDA reviews IND and IDE applications before trials may begin, and can impose a clinical hold if safety problems emerge. Grounds for a clinical hold include exposing participants to unreasonable risk, unqualified investigators, a misleading or incomplete investigator brochure, or a study protocol deficient in design.14eCFR. 21 CFR 312.42 – Clinical Holds and Requests for Modification
What Happens When Responsibility Fails
If the FDA has information that an investigator has repeatedly or deliberately failed to comply with the regulations, or has submitted false information to the FDA or the sponsor, the agency will initiate a disqualification proceeding. The investigator gets written notice and a chance to explain, and is offered a formal hearing if the explanation is not accepted. A disqualified investigator is declared ineligible to receive investigational products and barred from conducting any clinical investigation that supports an application for any FDA-regulated product, including drugs, biologics, devices, dietary supplements, and tobacco products.15eCFR. 21 CFR 312.70 – Disqualification of a Clinical Investigator
Sponsors face their own exposure. The FDA can issue notices of noncompliance for failures such as not registering a clinical trial, not submitting required information to ClinicalTrials.gov, or knowingly submitting false or misleading data. If a sponsor does not take corrective action within 30 days after receiving a notice, civil money penalties can follow, and more serious violations can lead to injunctions or criminal prosecution.16U.S. Food and Drug Administration. ClinicalTrials.gov – Notices of Noncompliance and Civil Money Penalty Actions A clinical hold can also delay a drug’s development by months or years.
When enforcement actions hit, the FDA looks first at who was responsible for the function that failed. For the investigational product as a whole, that answer traces back to the sponsor. For what happens with the product at a specific site, it traces to the investigator there. Everyone else in the picture, from CROs to study coordinators, is working under one of those two roles.